CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma (DLBCL).
  
  LEARNING OBJECTIVES

  • Apply available clinical research findings in the formation of evidence-based therapeutic approaches for patients with newly diagnosed and relapsed/refractory (R/R) DLBCL.
  • Appraise published Phase III trial data documenting the benefit of CD79b-targeted therapy as a component of first-line treatment for patients with DLBCL, and consider the implications of these findings for current clinical management algorithms.
  • Assess recently presented Phase III trial data documenting the benefit of various chimeric antigen receptor T-cell platforms as second-line therapy for patients with R/R DLBCL, and consider the ramifications of these findings for routine clinical decision-making.
  • Review pivotal clinical trial findings leading to the FDA approval of other novel compounds with unique mechanisms of action for R/R DLBCL, and identify patients for whom these approaches would be appropriate.
  • Evaluate the mechanisms of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with DLBCL, and consider the current clinical role of these agents.
  • Compare and contrast the side effects associated with available and emerging therapeutic strategies for patients with DLBCL, and formulate supportive care strategies to minimize and manage these toxicities.
  • Recall ongoing clinical research evaluating novel agents and strategies for DLBCL, and appropriately counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHDLBCL23/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Michael Dickinson, MD
  Hematologist
  Lead of Aggressive Lymphoma
  CAR-T Specialist
  Peter MacCallum Cancer Centre and Royal Melbourne Hospital
  Melbourne, Australia
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Adicet Bio, Bristol Myers Squibb, Genmab US Inc, Gilead Sciences Inc, Kite, A Gilead Company, Nkarta Inc, Novartis, Roche Laboratories Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Novartis, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc.
  
  Grzegorz S Nowakowski, MD
  Professor of Medicine and Oncology
  Chair, Lymphoid Malignancy Group
  Enterprise Deputy Director, Clinical Research
  Mayo Clinic Comprehensive Cancer Center
  Vice-Chair, Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, Bantam Pharmaceutical, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis Inc, Daiichi Sankyo Inc, Debiopharm, F Hoffmann-La Roche Ltd, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MEI Pharma Inc, MorphoSys, Ryvu Therapeutics, Seagen Inc, Selvita, TG Therapeutics Inc, Zai Lab.
  
  Gilles Salles, MD, PhD
  Service Chief, Lymphoma Service
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Advisory Committee: AbbVie Inc, Bristol Myers Squibb, Celgene Corporation, Genmab US Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Nurix Therapeutics Inc; Consulting Agreements: AbbVie Inc, atbtherapeutics, Bristol Myers Squibb, Celgene Corporation, Debiopharm, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Molecular Partners, Nordic Nanovector, Novartis, Nurix Therapeutics Inc, Orna Therapeutics; Contracted Research: Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: BeiGene Ltd.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Podcast Editor, Blood
  Vancouver, British Columbia, Canada
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.
  
  Jason Westin, MD, MS
  Director, Lymphoma Clinical Research
  Section Chief, Aggressive Lymphoma
  Professor, Department of Lymphoma and Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Monte Rosa Therapeutics, MorphoSys, Novartis, Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Novartis, Seagen Inc; Data and Safety Monitoring Board/Committee: Century Therapeutics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.
  
  Release date: January 2024
  Expiration date: January 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.